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Despite a long and valuable history, human-animal chimera research has often been questioned.
Among the moral issues raised by chimeras is the concept that integration of human cells into ana-
tomical locations such as the brain might endow animals with ‘‘human-like’’ capacities including self-
awareness. We present a justification for one type of human-animal chimera experiment: the evalu-
ation of hES cell developmental potency via teratoma formation in immunodeficient mice. We argue
that this experiment raises no significant moral concerns and should be the jurisdiction of animal care
and use committees and exempt from formal review by the stem cell research oversight process.Introduction
The classical representation of a chimera, such as that de-
scribed in Homer’s Iliad, is a mythical beast bearing the
body parts of several different creatures combined into
a single animal. The term chimera has a more tangible us-
age in modern science and medicine, where it indicates
organisms comprised of cells from two or more individuals
of the same or different species. Today, the most common
usage describes cellular combinations at the preimplanta-
tion blastocyst stage of development. That said, the term
also accurately reflects other entities created by introduc-
ing cells at later developmental stages including in adult
recipients. The fractional percentage and physiological in-
tegration of contributing cells will vary depending upon
when and where during development chimerism is estab-
lished, being high when early embryos are fused (Tarkow-
ski, 1961; Yu et al., 2002) and low when more differenti-
ated cells are introduced later in development, as in
clinical hematopoietic transplantation. Chimeras made
by transferring cells and tissues between different species
(xenotransplantation) have a lengthy history. The earliest
documented xenotransplants into humans used lamb or
calf blood and took place in mid 17th century Europe
(e.g., Lower and King, 1667), while the reverse (human
into animal) has been practiced as far back as the mid to
late 18th century (see Deschamps et al., 2005).
In the laboratory, animal hosts have long been used to
test human cells or tissues for basic research, particularly
in the study of malignancy (e.g., Hegner, 1913), as well as
in preclinical models for the evaluation of therapeutics.
One of the best examples of human cell engraftment into
animal hosts is the use of immunodeficient mice as trans-plant recipients for human stem and progenitors cells of
the hematopoietic system (Kamel-Reid and Dick, 1988;
Behringer, 2007).
Regulation of Human-Animal Chimera Research
The propriety and utility of evaluating human cells in ani-
mal models has been questioned (Karpowicz et al.,
2004; Robert, 2006; Streiffer, 2005). Experiments involv-
ing human-animal chimeras have further been the subject
of restrictive legislation (for example, in the U.S.A., see
Brownback [2005]) and raise the issue of how scientists
justify research in a particularly controversial area. To be-
gin with, the scientific objectives of every experiment must
be clearly reasoned, as a poorly articulated experimental
goal is unworthy of pursuit. Beyond this, studies involving
human-animal chimerism present a wide range and depth
of ethical issues (Hyun et al., 2007). However, the transfer
of human cells into postnatal, adult recipients is likely the
least contentious due to a low probability that human cells
introduced at such a late developmental stage may inte-
grate appreciably into existing structures (see Greene
et al., 2005; Robert, 2006; Streiffer, 2005). The prospect
that certain chimeras might adopt human features would
necessarily compel our moral interest in their fate and pro-
hibit certain experimental objectives (Robert, 2006), a con-
cern most pertinent to studies in which human neurons or
gametes might be incorporated into the brain or gonads,
respectively, of a closely related primate.
Considering the number of nations engaged in human
embryonic stem (hES) cell research worldwide, the topic
of how human-animal chimera research should be
regulated is of international relevance (e.g., House ofCell Stem Cell 1, September 2007 ª2007 Elsevier Inc. 253
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CommentaryCommons Science and Technology Committee on Guide-
lines for Human Embryonic Stem Cell Research, 2007).
Within the United States, a National Academy of Sciences
(NAS) panel has formulated guidelines for research on
hES cells that include specifications for experiments
involving human-animal chimeras and recommends that
Embryonic Stem Cell Research Oversight (ESCRO)
committees be formed to interpret the guidelines for local
experiments (National Research Council, 2005; National
Research Council, 2007). In their 2005 report (National
Research Council, 2005), the NAS made the following
recommendation:
‘‘All research involving the introduction of hES cells into
nonhuman animals at any stage of embryonic, fetal, or
postnatal development should be reviewed by the ESCRO
committee. Particular attention should be paid to the
probable pattern and effects of differentiation and integra-
tion of the human cells into the nonhuman animal tissues.’’
The International Society for Stem Cell Research
(ISSCR) has also compiled guidelines that further consider
issues relating to the conduct of stem cell research
beyond national borders (Daley et al., 2007; International
Society for Stem Cell Research Guidelines Taskforce,
2006) (downloadable at http://www.isscr.org/guidelines/).
In contrast to the NAS panel recommendations, the ISSCR
guidelines stipulate that the assay of hES cells by tera-
toma formation be accepted as routine and be exempt
from Stem Cell Research Oversight (SCRO) review. This
commentary explores the scientific rationale upon which
such recommendations are based.
The NAS and ISSCR guidelines invite thoughtful consid-
eration. Any type of human-animal chimera experiment
should be scrutinized for which tissues will be chimerized
(either purposefully or inadvertently), for the degree of chi-
merism that might result, and for the state of physiologic
integration of the engrafted cells. Although the guidelines
are most relevant to the purposeful chimerism of specific
tissues like the brain, we must consider inadvertent chi-
merism in the context of other assays and determine the
likelihood that human cells might migrate and establish
themselves in other locations. Indeed, the ESCRO com-
mittee at our home institution raised concerns about the
prospects for even a small contribution of cells to the
mouse brain or germline during routine hES cell teratoma
formation assays and asked that we justify these experi-
ments in scientific terms.
The Assay of hES Cells In Vivo via Teratoma
Formation, One Type of Human-Animal Chimera
For murine ES cells, the truest demonstration of cellular
pluripotency is assayed in vivo via blastocyst chimerism
or tetraploid aggregation followed by gestation (Brinster,
1974; Nagy et al., 1990). When considering human ES
cells, such experiments are clearly ethically proscribed.
The adult murine host, however, contains permissive
niches that support the growth and differentiation of hES
cells into a wide variety of cell and tissue types and may
be employed in a less robust, though informative, surro-
gate assay: in vivo teratoma formation (Brivanlou et al.,254 Cell Stem Cell 1, September 2007 ª2007 Elsevier Inc.2003; Thomson et al., 1998). When introduced into adult,
immunodeficient mouse hosts by subcutaneous, intra-
muscular, or intratesticular routes, hES cells will sponta-
neously form teratoma-like masses containing ectoderm
such as nerve and skin; mesoderm including bone, blood,
and muscle; and endoderm or gut tissue (Thomson et al.,
1998). Formation of differentiated cells from the three so-
matic germ layers within the teratoma is taken as the best
indicator of the pluripotency of hES cell lines (Brivanlou
et al., 2003). Of note, while some recently reported ‘‘plurip-
otent’’ cell lines from nonembryonic sources have proven
capable of forming multiple tissue types in vitro, they were
incapable of forming teratoma-like masses in vivo (De
Coppi et al., 2007), an indication of incomplete potency
when compared to hES cells and a challenge to the accu-
racy of their description as pluripotent.
Paraffin sections of hES cell-derived teratomas are
highly informative, and though variable degrees of differ-
entiation are often present, many tissue types as well as
three-dimensional organ architecture may be noted (see
Figure 1). A ‘‘gold standard’’ for evaluating the quality of
hES cells includes the idea that a cell line must form
a well-differentiated, teratoma-like mass (Brivanlou
et al., 2003). Recently, a multinational study organized to
evaluate hES cell lines worldwide included teratoma for-
mation as a feature of their analysis (Adewumi et al.,
2007), and a working group of the ISSCR has further for-
mulated a set of ‘‘standard conditions’’ for hES-derived
teratomas (Gertow et al., 2007). If a hES line fails in this
most basic of developmental tests, it may still remain
a valuable research tool, albeit a restricted one, due to
an impaired capacity to form the many tissues under study
by scientists. Such a differentiation failure might also sug-
gest a dangerously flawed cellular resource for use in fu-
ture therapies. As such, the need for teratoma assays
with hES cells is compelling. That said, special ethical as
well as regulatory caveats are to be considered when
introducing hES cells into animal hosts.
History and Classification of Naturally Occurring
Pluripotent Cell Tumors
In responding to the specific question of whether or not
experimental teratoma derivatives in fact migrate beyond
the tumor margins and significantly integrate distally, one
may literally draw upon centuries of information regarding
the pathogenesis of pluripotent cell tumors in both human
patients and, more recently, experimental animals. The
term ‘‘teratoma’’ was introduced by Rudolf Virchow in
his 1863 collection ‘‘Die krankhaften Geschwu¨lste,’’ al-
though such tumors were well known prior to his work, in-
cluding an illustrated contribution to the Philosophical
Transactions of the Royal Society from the year 1683
(Birch and Tyson, 1683). In general, pluripotent cell-
derived tumors are categorized by their developmental
potential, cellular origin, and anatomic location and
include sacrococcygeal teratoma, gonadoblastoma, and
dermoid cysts of the ovary, among others. Teratomas
are a subset of pluripotent tumors associated with germ
cells (Andrews, 1988; Askanazy, 1907; Teilum, 1965),
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Histology of a human teratoma formed by subcutaneous injection of the NIH-approved human embryonic stem cell line H9 (Thomson et al., 1998) into
an immune-deficient mouse host. Teratomas are pluripotent tumors, i.e., containing derivatives of all three embryonic germ layers (ectoderm, me-
soderm, and endoderm), as illustrated here. Though chaotically arrayed within the mass, functional, organ-specific architecture may develop as dem-
onstrated in (C), where layers of gut endoderm secrete muscinous material into a central lumen toward the upper left. (A) Low-resolution image of
a whole teratoma demonstrating a complex, highly cystic mass (scale bar, 1.0 mm). (B) Cartilage (mesoderm). (C) Colonic gut epithelium (endoderm).
(D) A rivulet of muscle at arrow (mesoderm). (E) Respiratory, brush-border, epithelium (endoderm). (F) Glycogenated squamous epithelium (ecto-
derm). (B) was photographed at 2003magnification and (C)–(F) at 1003 and represent different areas within a single teratoma. All images were ob-
tained from formalin-fixed and paraffin-embedded teratoma sections stained with hematoxylin and eosin.although they may also arise in extragonadal areas key to
fetal primordial germ cell migration (Witschi, 1948) includ-
ing sites throughout the mediastinum, the central region of
the thoracic cavity.
With regard to histopathology, teratomas are character-
ized as either mature and benign (i.e., containing well-
defined somatic structures) or as immature and malignant
(bearing a large degree of embryonic neural derivatives or
masses of undifferentiated, ‘‘embryonal carcinoma’’ [EC]
cells). Though regions of benign, multidifferentiated tissue
may be noted in immature teratomas, tumors containing
EC cells are appropriately termed ‘‘teratocarcinomas’’
(Andrews, 2002) to reflect their tendency to evolve towardmalignancy. The distinct natural history of teratocarci-
nomas also correlates with their transplantability in exper-
imental systems (Kleinsmith and Pierce, 1964).
The majority of naturally occurring teratomas are well-
defined, benign masses (Isaacs, 2004) that fail to meta-
stasize, can be eliminated surgically, and typically do not
reoccur. When metastasis is noted, it is most often a result
of overlooked microscopic inclusions of a more malignant
phenotype such as yolk sac tumor within an otherwise
benign-appearing teratoma. There are also overtly mali-
gnant primary tumors that contain a paucity of well-
differentiated elements and include seminoma and nonse-
minomatous germ cell tumors in males, dysgerminoma inCell Stem Cell 1, September 2007 ª2007 Elsevier Inc. 255
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in both genders. The behavior of germ cell-related tumors
varies substantially between the sexes; e.g., certain tumor
types have a much higher incidence in females, and male
gonadal tumors are more likely to behave as a malignancy
than their female counterparts. Naturally occurring tera-
tomas and related tumors are abnormal, neoplastic
pathologies bearing genetic defects. In contrast, experi-
mentally induced teratoma-like masses, including those
formed from hES cells, result from normal pluripotent cells
transplanted to growth-permissive, ectopic sites.
Early Teratomas in the Laboratory
Experimentally, the first robust teratoma studies were
conducted by Stevens and Little in the 129 inbred strain
of laboratory mouse, which they noted was genetically
predisposed to testicular teratoma (Stevens and Little,
1954). These observations permitted the eventual isola-
tion of the stem cell component of the teratoma (Klein-
smith and Pierce, 1964; Martin and Evans, 1974), the
aforementioned EC cell, thus founding the field of pluripo-
tent stem cell research as we know it. Additionally, trans-
plantation of entire egg cylinder or genital ridge stage
embryos to ectopic sites in host recipients initiates nonin-
vasive and nonmetastatic teratoma-like tumors (Solter
et al., 1970; Stevens, 1968). These ectopic masses have
at times been referred to as teratocarcinomas in the liter-
ature due to foci of undifferentiated stem cells (EC) and oc-
casional serial transplantability with or without the capac-
ity to establish cell lines when explanted into tissue
culture. Such cell lines (e.g., P19, McBurney and Rogers
[1982]) are perhaps neither EC nor ES cells but, rather,
outgrowths of primordial germ cells (PGCs) and may fur-
ther be genetically abnormal (McBurney, 1976).
A logical extension of such work asked whether plurip-
otent cells could be isolated from nontumor tissues, and to
date, ES cells have been obtained from the normal, pre-
implantation embryos of several species including mice
(Evans and Kaufman, 1981; Martin, 1981) and humans
(Thomson et al., 1998). The fullest developmental potential
of mouse pluripotent cells is assayed via the formation of
blastocyst or tetraploid chimeras that are then gestated in
the uterus of host mice (Brinster, 1974; Nagy et al., 1990).
Pluripotency is demonstrated when the progeny of the in-
put cells are found in all tissues, including the germline.
Obvious ethical prohibitions preclude similar work with
hES cells. Thus, the range of hES tissue fates is assessed
using the surrogate assay of transfer into adult immune-
deficient mice, where the resulting teratoma-like out-
growths offer important insights into the development
plasticity of individual cell lines. The majority of such
masses resemble naturally occurring teratomas that
would be classified as mature, reflecting the normal, non-
malignant origins of the ES cells.
Summary
Considering these observations, several key points
emerge. First, the origins of hES cells are not as isolates
from abnormal, neoplastic tissues (as is the case with256 Cell Stem Cell 1, September 2007 ª2007 Elsevier Inc.EC cells) but rather from normal blastocysts. Human ES
cell-derived tumors that form following injection into im-
mune-deficient mice are mature, encapsulated (Gertow
et al., 2007; Reubinoff et al., 2000; and see Figure 1A),
easily resected, and do not invade beyond the local tissue.
Analogous, naturally occurring masses (i.e., true tera-
tomas) in human patients respond well to surgical treat-
ment and do not metastasize. While the initiation of hES
cell-derived masses is not biologically equivalent to natu-
rally occurring teratomas, the growth, presentation at nec-
ropsy, and histopathology of each are quite similar, and
we conclude that the behavior of experimentally produced
teratomas is well informed by their clinical counterparts.
Thus, hES cell migration beyond the tumor mass and
into the host brain is not expected in the experimental
setting, and the inadvertent migration of normal hES cells
into the adult mouse gonad, a niche permissive for
pluripotent cells, is likewise unexpected. Furthermore,
the species barrier between humans and mice prevents
crossfertilization of gametes. Moreover, it is a simple
matter to segregate transplant recipients according to
sex or to use only a single sex for all experiments. The
remainder of our analysis will focus on the potential for
neural integration.
Second, while an unexpected result could occur
wherein an aberrant or genetically perturbed hES cell
line yielded a metastatic tumor with neural elements, the
tissue in such tumors is primarily of a very immature, em-
bryonal nature (Paterakis et al., 2005). Absent additional
neuronal maturation, such tissue is unlikely to form the in-
tegrative networks that participate in higher-order neural
interactions including those required for cognition or per-
ception. Experimental systems have been developed that
make use of human teratocarcinoma-derived embryonal
carcinoma cells such as the EC line NTERA2 (Andrews
et al., 1984). NTERA2 bears a robust propensity for neural
progenitor differentiation following treatment with retinoic
acid (Andrews, 1984). While these neural derivatives
(termed NT2N) are immature in vitro (Pleasure and Lee,
1993), it has been shown that they are capable of long-
term survival and neuronal process extension in an
in vivo model, demonstrating markers of additional matu-
ration within 4 to 6 months following engraftment into
immune-deficient murine recipients (Kleppner et al.,
1995). However, it is important to stress that while the
host environment was capable of refining the maturation
of the NT2N cells, antecedent neuronal differentiation
with retinoic acid was required prior to engraftment. The
concern for relevant integration into the host brain during
teratoma assays is further lessened by the fact that exper-
imental hosts are adult mice with well-developed and in-
tact central nervous system architecture. Additionally,
while certain structures found in experimental and
naturally occurring teratomas can exhibit remarkable
completeness of differentiation such as complete teeth
(Birch and Tyson, 1683) the degree of tissue organization
required for organ function has not been observed for
even the simplest concerted actions (e.g., chewing), let
alone higher brain function.
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somehow migrate to the brain and create complex neural
networks, the possibility of the manifestation of any higher
human-like brain function confined within a mouse’s body
is remote. This conviction is based upon recent studies in
which functional human-rodent brain chimerism was the
explicit experimental aim (Brustle et al., 1998; Flax et al.,
1998; Kerr et al., 2003; Mueller et al., 2005; Nistor et al.,
2005; Tabar et al., 2005). Such work indicates that graft-
derived human neurons and support cells respond to the
mouse host environment, integrating into existing struc-
tures rather than patterning the host to have more
human-like brain architecture. Not a single case has
been reported in which host brain function was improved
beyond control levels following human neuron or precur-
sor cell grafting, even when functional improvement of
the nervous system was the objective (Kerr et al., 2003;
Mueller et al., 2005). It seems quite unlikely that small
numbers of metastatic teratoma derivatives could prove
more effective at functional neuronal engraftment. This
conclusion is in accordance with a small but growing
body of literature on the ethics of human-animal chimeras
that agrees on the general notion that the use of remotely
related, noninjured, adult animal recipients presents the
least moral concern, particularly if tissue replacement or
restoration of function is not the experimental objective.
This is in contrast to the injection of human cells or tissues
into closely related, developing, or injured organisms (see
Greene et al., 2005; Karpowicz et al., 2004; Robert, 2006;
Streiffer, 2005; Hyun et al., 2007).
Finally, our human experience perhaps serves as the
strongest argument against the possibility that scant neu-
ral derivatives of hES cells might serve to ‘‘humanize’’ the
mouse. We are aware of the latency between the forma-
tion of the most nascent neural structures in utero during
human development and the onset of consciousness,
the ability to consider abstract principles, and the capacity
to articulate (either verbally or physically) individual will or
need. The possibility that even extensive chimerism of the
mouse brain by human neurons would result in anything
remotely approaching an ethically concerning state
seems extremely unlikely indeed (Karpowicz et al.,
2004), especially considering the short duration of tera-
toma assays (typically less than 3 months).
Taken together, we believe that the risk of inadvertently
creating a rodent chimera with higher, human brain func-
tion is negligible. Indeed, a recent analysis by a multi-
disciplinary working group exploring the moral issues
surrounding human/nonhuman primate (NHP) neural
grafting concluded that it is ‘‘.unlikely that the grafting
of human cells into healthy adult NHPs will result in signif-
icant changes in morally relevant mental capacities’’
(Greene et al., 2005). In our opinion, the risk that teratoma
formation assays might endow higher cognitive function in
an even more distantly related species such as the mouse
is so improbable as to obviate the need for experimental
limitations beyond those normally in place for other types
of animal experimentation. Simple notification that tera-
toma formation experiments are to be conducted shouldprove sufficient for regulatory bodies charged with review-
ing hES cell research, as the full oversight of such exper-
iments will continue to be the jurisdiction of animal care
and use committees.
Conclusion
The formation of hES cell-derived teratomas in experi-
mental rodents represents the most robust and ethically
permissible standard for evaluating the developmental
versatility of hES cells. This form of human-animal chimera
yields unique experimental insights of irreplaceable value
(Brivanlou et al., 2003). Teratoma formation is described in
instructional materials made available to federally funded
investigators using National Institutes of Health (NIH)-
approved hES cell lines (see http://stemcells.nih.gov/).
Furthermore, the important experimental insights gained
by such studies are of enormous worth in our efforts to un-
derstand the developmental biology of human tissues, ex-
periments that are only possible due to the availability of
hES cells. In conclusion, it is our opinion that human tera-
toma formation studies in adult mice are justifiable and
should be routinely approved by animal care committees
with a minimal need for regulation by the stem cell
research oversight process.
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